Q-Line Biotec SME: Check IPO Date, Live Subscription and Key Details
Q-Line Biotech Limited, incorporated in 2010 (originally as POCT Services Private Limited), is an Indian diagnostics and in-vitro diagnostics (IVD) enterprise. The company is actively engaged in developing, manufacturing, and marketing a diverse range of medical reagents, consumable testing kits, point-of-care (POC) devices, and automated pathology equipment. Serving diagnostic laboratories, hospitals, and medical colleges directly and through an expansive national distributor network since 2013, its operational capabilities span fields like Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics.
Price Range
₹326.0 - ₹343.0
Issue Size
₹214.48 Cr
Lot Size
400 shares
IPO Type
NSE SME
GMP
₹113(+32.94%)
Est. Listing Price
₹456
Estimate Profit
₹90,400
Retail Portion
35.00%
Key Metrics
Check Live GMPGMPFace Value
₹10
EPS
-
P/E Ratio
-
RoNW
16.88%
ROE
16.88%
Debt to Equity
1.06
Advertisement
Timeline
IPO Opens
21 May
IPO Closes
25 May
Allotment
26 May
Listing
29 May
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 21 May 2026 | Subscription starts |
| IPO Close Date | 25 May 2026 | Subscription ends |
| Allotment Date | 26 May 2026 | Allotment |
| Listing Date | 29 May 2026 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Individual | 2 | ₹2,74,400 |
SHNI (Min) | 3 | ₹4,11,600 |
SHNI (Max) | 7 | ₹9,60,400 |
BHNIAbove ₹10,00,000 | 8 | ₹10,97,600 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 49.99% |
| NII (Non-Institutional Investor) | 15.01% |
| Retail | 35.00% |
| Market Maker | 5.01% |
| Total | 100.00% |
IPO Objectives
- To meet the working capital requirements of the company (₹93.50 Cr).
- Full or partial repayment or prepayment of certain outstanding borrowings availed by the company (₹90.00 Cr).
- General Corporate Purposes.
Strengths
- The company features an In-House R&D Stack with deep technical expertise focused on domestic reverse engineering, new tool layout, and rigorous quality verification pipelines.
- It commands a Comprehensive IVD Reach through a diverse, multi-tier product catalog tailored to the fast-growing, multi-billion dollar in-vitro diagnostics industry.
- The business leverages a Widespread Distribution Framework with operational footprints firmly anchored across all four core geomorphic zones of the Indian market.
- It maintains a Stable Customer Footprint built on long-standing contractual relations with core medical service groups, premium clinical networks, and medical universities.
Weaknesses
- The company faces Capital Pipeline Stress due to a heavy internal structural dependency on working capital cycles, with ₹93.50 Cr of fresh money deployed explicitly for operating lines.
- It exhibits High Leverage Ratios, carrying a significant leverage profile with total debts building up to ₹243.85 Cr by December 2025, which heavily eats into overall capital flexibility.
- The business shows a critical Net Worth Degradation, with reported net worth slipping to -₹0.04 Cr in the latest 9M period ending December 2025, flagging severe short-term balance sheet risks.
- It operates in a highly Fragmented Marketplace, dealing with deep, localized sector rivalry from unorganized local manufacturers alongside well-capitalized multi-national healthcare corporations.
Advertisement
Financial Performance
| Period Ended | 31 Dec 2025 (9M) | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 561.34 | 455.49 | 339.25 | 251.58 |
| Revenue (₹ Cr.) | 236.5 | 322.58 | 206.45 | 184.81 |
| PAT (₹ Cr.) | 38.69 | 28.13 | 34.44 | 32.1 |
| Net Worth (₹ Cr.) | -0.04 | 189.95 | 161.81 | 127.37 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|
Subscription Details
Daily Bids Status
| Category | Day 1 |
|---|---|
| QIB | 4.15x |
| NII | 5.26x |
| S-HNI | 4.08x |
| B-HNI | 5.85x |
| RII | 3.71x |
| Total | 4.17x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 11,88,000 | 49,29,600 | 169.09 |
| NII | 8,91,600 | 46,87,600 | 160.78 |
| Small NII | 2,97,200 | 12,12,000 | 41.57 |
| Big NII | 5,94,400 | 34,75,600 | 119.21 |
| RII | 20,79,200 | 77,16,800 | 264.69 |
| Total | 41,58,800 | 1,73,34,000 | 594.56 |
Advertisement
Company Details
- Q-Line Biotech Ltd.
- 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012
- +91 522-2435570
- compliance@qlinebiotech.com
- https://www.qlinebiotech.com/
Registrar Details
- Purva Sharegistry (India) Pvt.Ltd.
- +91 22 4961 4132
- support@purvashare.com
- https://www.purvashare.com/
Frequently Asked Questions
What does Q-Line Biotech do?
Q-Line Biotech operates in the biotechnology and diagnostics sector. The company manufactures medical reagents, consumables, point-of-care (POC) devices, and pathology products used by hospitals and laboratories.
What are the IPO dates for Q-Line Biotech SME IPO?
The Q-Line Biotech SME IPO will open for subscription on May 21, 2026, and close on May 25, 2026.
What is the price band and minimum investment for Q-Line Biotech IPO?
The IPO price band is fixed at ₹326 to ₹343 per share. Retail investors need to apply for a minimum of 2 lots (800 shares), requiring an investment of ₹2,74,400 at the upper price band.
What is the Grey Market Premium (GMP) of Q-Line Biotech IPO today?
As of May 18, 2026, the Grey Market Premium (GMP) of Q-Line Biotech IPO is around ₹42 per share, indicating an estimated listing price of about ₹385.
Where will Q-Line Biotech IPO be listed?
Q-Line Biotech IPO is proposed to be listed on NSE SME (NSE Emerge), with the tentative listing date set for May 29, 2026.
Loading comments...